Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Oruka Therapeutics, Inc. (ORKA : NSDQ)

• Company Description    Oruka Therapeutics Inc. is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka Therapeutics Inc., formerly known as ARCA biopharma Inc., is based in WESTMINSTER, Colo. Number of Employees: 36

• Price / Volume Information    Yesterday's Closing Price: $27.75 Daily Weekly Monthly 20 Day Moving Average: 454,096 shares Shares Outstanding: 41.54 (millions) Market Capitalization: $1,152.77 (millions) Beta: -0.30 52 Week High: $29.64 52 Week Low: $5.49 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 13.31% 10.34% 12 Week 80.55% 73.06% Year To Date 43.12% 25.10%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 855 OAK GROVE AVENUE SUITE 100 - MENLO PARK,CA 94025 USA ph: 650-606-7910 fax: 720-208-9261 ir@orukatx.com https://orukatx.com

• General Corporate Information    Officers Lawrence Klein - Chief Executive Officer & Director Samarth Kulkarni - Chairman Arjun Agarwal - Senior Vice President; Finance and Treasurer Kristine Ball - Director Carl Dambkowski - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 687604108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/12/25 Share - Related Items Shares Outstanding: 41.54 Most Recent Split Date: 9.00 (0.08:1) Beta: -0.30 Market Capitalization: $1,152.77 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.55 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.09 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/12/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.05 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 78.71% vs. Previous Quarter: -15.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - -26.26 03/31/25 - -25.66 ROA 09/30/25 - - 06/30/25 - -24.16 03/31/25 - -23.39 Current Ratio 09/30/25 - - 06/30/25 - 27.42 03/31/25 - 30.03 Quick Ratio 09/30/25 - - 06/30/25 - 27.42 03/31/25 - 30.03 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - 9.10 03/31/25 - 9.66 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©